Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systolic Hypertension Clear all
Active, not recruiting Phase 2 Interventional

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
Drug · Other
Lead sponsor
Rong Zhang
Other
Eligibility
60 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vitamin D and Blood Pressure

NCT00459563
View directory record Official record
Conditions
Hypertension
Interventions
Vitamin D, calcitriol, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Not applicable Interventional

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

NCT04467879
View directory record Official record
Conditions
Hypertension, Systolic
Interventions
Zona Plus Device, Control Device
Device
Lead sponsor
Zona Health, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
St Louis, Missouri • Charlotte, North Carolina • Goldsboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Withdrawn No phase listed Observational

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional

Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

NCT00089713
View directory record Official record
Conditions
Hypertension
Interventions
alagebrium chloride (ALT-711)
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

NCT00350168
View directory record Official record
Conditions
Hypertension
Interventions
valsartan + amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

NCT00939640
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

NCT06962488
View directory record Official record
Conditions
Hypertension, Atherosclerotic Cardiovascular Disease
Interventions
Regular Care, SBP PRS Dissemination
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Physiological Effects of Grape Seed Extract in Diastolic Heart Failure

NCT01185067
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
Interventions
grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Minding GOALS: An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control

NCT02694432
View directory record Official record
Conditions
Hypertension
Interventions
GOALS, Minding GOALS
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

2 Weeks of Citrulline Supplementation on Arterial Function in Postmenopausal Women With Elevated Blood Pressure or Hypertension

NCT06025383
View directory record Official record
Conditions
Menopause, Hypertension
Interventions
L-Citrulline, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

NCT05800145
View directory record Official record
Conditions
Hypertension
Interventions
Resource information Supplemental Nutrition Assistance Program (SNAP), community health worker (CHW), medically tailored meals
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

NCT00772577
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide, Ramipril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional Results available

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

NCT00170950
View directory record Official record
Conditions
Hypertension
Interventions
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
11,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

24 Hour Ambulatory Cardiac Oxygen Consumption

NCT05170061
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Valsartan, Nebivolol/valsartan combination
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome

NCT00940966
View directory record Official record
Conditions
Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions
standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet
Dietary Supplement
Lead sponsor
CAMC Health System
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

NCT00185068
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
16
States / cities
Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

NCT07109739
View directory record Official record
Conditions
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Interventions
POWERbreathe K5
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

NCT00802893
View directory record Official record
Conditions
Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions
6R-BH4, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 10, 2026, 4:40 PM EDT